This medication is a HER2-targeted antibody and microtubule inhibitor, prescribed as a single medicine for the treatment in patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. .
IV- The recommended dose is 3.6 mg/kg every 3 weeks (21-day cycle).
It comes as powder for injection (diluted with fluid), to be administered by a healthcare provider into the vein.
• Caution should be exercised in patients with history of liver or heart problem, any allergy, who are taking other medications, elderly, children, during pregnancy and breastfeeding.
• Ado-trastuzumab emtansine should not be administered at doses greater than 3.6 mg/kg.
• Should not substitute for or with trastuzumab.
• Monitor platelet counts prior to each dose of this drug administration.
• Perform HER2 testing while taking this medication.
• Discontinue this medication in patients diagnosed with interstitial lung disease or pneumonitis.
• Serious Effects :
Lung problems, injection site reactions, nerve damage, heart damage, embryo-fetal toxicity.
• Most Common : Fatigue, nausea, muscle and bone pain, decrease in platelet counts, headache, increased level of liver enzymes and constipation.
• Miscellaneous : Tiredness, liver problems, nerve problems.
Avoid excess dosage.
Store vials in a refrigerator at 2°C to 8°C.
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All